ARS Pharmaceuticals Inc. (SPRY)
NASDAQ: SPRY
· Real-Time Price · USD
14.20
0.23 (1.65%)
At close: May 01, 2025, 3:59 PM
14.21
0.11%
After-hours: May 01, 2025, 05:26 PM EDT
Company Description
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites.
Its product includes Neffy, a low-dose intranasal epinephrine nasal spray.
The company was incorporated in 2015 and is based in San Diego, California.
ARS Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Richard Lowenthal M.B.A., M.S., MSMSEL |
Contact Details
Address: 3525 Del Mar Heights Road San Diego, California United States | |
| Website | https://ars-pharma.com |
Stock Details
| Ticker Symbol | SPRY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671858 |
| CUSIP Number | 82835W108 |
| ISIN Number | US82835W1080 |
| Employer ID | 81-1489190 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary |
| Kathleen D. Scott CPA | Chief Financial Officer |
| Daniel Relovsky | Senior Vice President of Marketing |
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer |
| Eric Karas | Chief Commercial Officer |
| Harris Kaplan M.B.A. | Executive Vice President of Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 08, 2025 | 4 | Filing |
| Mar 24, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 20, 2025 | S-8 | Filing |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 4 | Filing |